Clinically relevant drug interactions with multikinase inhibitors: a review
Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience for the patient, challenges arise in the use of MKIs. A...
Main Authors: | Koen G. A. M. Hussaarts, G. D. Marijn Veerman, Frank G. A. Jansman, Teun van Gelder, Ron H. J. Mathijssen, Roelof W. F. van Leeuwen |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835918818347 |
Similar Items
-
Rare complications of multikinase inhibitor treatment
by: Fabián Pitoia, et al. -
Multikinase inhibitors use in differentiated thyroid carcinoma
by: Jasim S, et al.
Published: (2014-12-01) -
Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma
by: Chiara Paglino, et al.
Published: (2011-12-01) -
Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
by: Filip Miljković, et al.
Published: (2018-01-01) -
Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
by: Lin T, et al.
Published: (2017-04-01)